Quantcast

Latest Atrophic vaginitis Stories

2013-06-25 23:22:48

New Campaign FindingtheWords.com Increases Awareness About Painful Intercourse Due to Menopause and Encourages Women to Speak Up to Their Doctors (PRWEB) June 25, 2013 Academy Award-nominated actress Virginia Madsen is never one to shy away from a conversation, even if the topic at first blush seems awkward or embarrassing. Impacting many women in the United States (U.S.), painful intercourse due to menopause is one of the most bothersome symptoms of a chronic and progressive medical...

2013-05-30 23:17:33

This June, a new commercial for Bescot Healthcare Canada produced by television agency Creative Bube Tube will begin advertising Zestica Moisture: a natural feel, non-hormonal personal hydrogel lubricant for post-menopausal women that naturally introduces moisture back into the vagina. In a recent user trial 98% of women found relief of vaginal dryness one hour after use. Toronto, Ontario (PRWEB) May 30, 2013 As the years go by, we all grow a little wiser and our older bodies aren´t...

2011-08-17 07:00:00

RED BANK, N.J., Aug. 17, 2011 /PRNewswire/ -- A new HealthyWomen survey of postmenopausal women reveals that many of them are embarrassed to discuss the vaginal and sexual symptoms of menopause with their health care professional and with their partner. Among the survey respondents who did discuss their symptoms with their health care professional, over one quarter said they waited more than two years before doing so. Many of the postmenopausal women surveyed who had not spoken with their...

2010-10-07 04:00:00

LONDON, October 7, 2010 /PRNewswire/ -- To mark World Menopause Day on 18th October 2010, the International Menopause Society (IMS) is launching new Recommendations for the management of postmenopausal vaginal atrophy, a distressing condition that will affect up to half of women after menopause.[1] This new guidance is essential as, according to new research, one in two women with vaginal atrophy (VA) will live with their condition unnecessarily for over three years, despite effective...

2010-08-23 08:00:00

PRINCETON, N.J., Aug. 23 /PRNewswire-FirstCall/ -- Novo Nordisk Inc. today announced that it has signed an exclusive agreement with Upsher-Smith Laboratories, Inc. to market Vagifem® (estradiol vaginal tablets) 10 mcg. Under the terms of the agreement, Upsher-Smith will exclusively market Vagifem® 10 mcg to physicians in the U.S. beginning August 2 through the company's existing field sales force. Novo Nordisk introduced Vagifem® 10...

2010-05-20 07:45:00

PRINCETON, N.J., May 20 /PRNewswire/ -- Novo Nordisk Inc. announced today that Vagifem® (estradiol vaginal tablets) 10 mcg will become the only available formulation of Vagifem® in the U.S., in line with medical recommendations for women to use the lowest effective estrogen dose to treat the symptoms of atrophic vaginitis due to menopause. The company will discontinue the sale of Vagifem® 25 mcg tablets in the U.S. on July 30, 2010....

2009-12-02 08:00:00

PRINCETON, N.J., Dec. 2 /PRNewswire-FirstCall/ -- Novo Nordisk said today that the U.S. Food and Drug Administration (FDA) has approved a 10 mcg dose formulation of Vagifem® (estradiol vaginal tablets) for the treatment of atrophic vaginitis due to menopause - a condition experienced by up to 75 percent of postmenopausal women. This approval makes Vagifem® 10 mcg the lowest local estrogen therapy (LET) dose commercially available in the U.S. It will be...

2009-09-10 07:00:00

ANN ARBOR, Mich., Sept. 10 /PRNewswire/ -- QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive efficacy results from the second of two patient cohorts in the second pivotal Phase 3 study for Ophena(TM) (ospemifene tablets), the company's investigational compound in development for the treatment of postmenopausal vulvovaginal atrophy (VVA). This study, together with the recent completion of a long-term safety study for Ophena(TM), marks the...

2009-07-29 07:00:00

ANN ARBOR, Mich., July 29 /PRNewswire/ -- QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive top-line efficacy results from the first of two patient cohorts in its second pivotal Phase 3 trial of the investigational compound, Ophena(TM) (ospemifene tablets), for the treatment of postmenopausal vulvovaginal atrophy (VVA). The Company has also successfully completed two long term safety extension studies from its first pivotal Phase 3...

2009-03-31 07:00:00

ANN ARBOR, Mich., March 31 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company, today announced that it has completed enrollment in the Company's second pivotal Phase 3 clinical trial of Ophena(TM) (ospemifene tablets). Together with the previously completed first pivotal Phase 3 study of Ophena(TM), the Company has fully enrolled its planned pivotal Phase 3 studies for Ophena(TM), the most advanced estrogen-free oral therapy currently in development for the...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related